In the canagliflozin and renal events in diabetes with established nephropathy clinical evaluation (CREDENCE) trial, i.e., estimated GFR of 30 to <90ml/min/1.73m2 or albuminuria clinical evaluation, that was aborted early after the primary endpoints were reached, the SGLT2 inhibitors were effective in delaying the progression of CKD and reducing albuminuria. This evidence concerns the gene SLC5A2 and diabetes mellitus.